PURPOSE: Quantitative relationships between 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) concentrations and lymphosuppression have not been reported, but would be useful for regimen design. A population pharmacokinetic/pharmacodynamic model was constructed in this study using data from 41 hematopoietic cell transplant (HCT) recipients conditioned with busulfan in combination with fludarabine (total dose 120 mg/m², Protocol 1519) or with fludarabine (total dose 250 mg/m²) with rabbit antithymocyte globulin (rATG, Protocol 2041). METHODS: Individual pharmacokinetic parameters were fixed to post hoc Bayesian estimates, and circulating absolute lymphocyte counts (ALC) were obtained during the 3 weeks prior to graft infusion. A semi-physiological cell-kill model with three lymphocyte transit compartments was applied and aptly characterized the time course of suppression of circulating ALC by fludarabine administration. Drug- and system-specific parameters were estimated using a maximum likelihood expectation maximization algorithm, and the final model was qualified using an internal visual predictive check. RESULTS: The final model successfully characterized the time course and variability in ALC. Pharmacodynamic parameters exhibited considerable between subject variability (38.9-211 %). The HCT protocol was the only covariate associated with the pharmacodynamic parameters, specifically the lymphocyte kill rate, the transit rate between lymphocyte compartments, and the baseline ALC. CONCLUSIONS: This model can be used to simulate the degree of lymphosuppression for design of future fludarabine-based conditioning regimens.
PURPOSE: Quantitative relationships between 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) concentrations and lymphosuppression have not been reported, but would be useful for regimen design. A population pharmacokinetic/pharmacodynamic model was constructed in this study using data from 41 hematopoietic cell transplant (HCT) recipients conditioned with busulfan in combination with fludarabine (total dose 120 mg/m², Protocol 1519) or with fludarabine (total dose 250 mg/m²) with rabbit antithymocyte globulin (rATG, Protocol 2041). METHODS: Individual pharmacokinetic parameters were fixed to post hoc Bayesian estimates, and circulating absolute lymphocyte counts (ALC) were obtained during the 3 weeks prior to graft infusion. A semi-physiological cell-kill model with three lymphocyte transit compartments was applied and aptly characterized the time course of suppression of circulating ALC by fludarabine administration. Drug- and system-specific parameters were estimated using a maximum likelihood expectation maximization algorithm, and the final model was qualified using an internal visual predictive check. RESULTS: The final model successfully characterized the time course and variability in ALC. Pharmacodynamic parameters exhibited considerable between subject variability (38.9-211 %). The HCT protocol was the only covariate associated with the pharmacodynamic parameters, specifically the lymphocyte kill rate, the transit rate between lymphocyte compartments, and the baseline ALC. CONCLUSIONS: This model can be used to simulate the degree of lymphosuppression for design of future fludarabine-based conditioning regimens.
Authors: Dong Hwan Kim; Jong Gwang Kim; Sang Kyun Sohn; Woo Jin Sung; Jang Soo Suh; Kun Soo Lee; Kyu Bo Lee Journal: Br J Haematol Date: 2004-04 Impact factor: 6.998
Authors: Martin Bornhauser; Barry Storer; John T Slattery; Frederick R Appelbaum; H Joachim Deeg; John Hansen; Paul J Martin; George B McDonald; W Garrett Nichols; Jerald Radich; Ann Woolfrey; Andreas Jenke; Eberhard Schleyer; Christian Thiede; Gerhard Ehninger; Claudio Anasetti Journal: Blood Date: 2003-04-03 Impact factor: 22.113
Authors: W Plunkett; V Gandhi; P Huang; L E Robertson; L Y Yang; V Gregoire; E Estey; M J Keating Journal: Semin Oncol Date: 1993-10 Impact factor: 4.929
Authors: J B Langenhorst; C van Kesteren; E M van Maarseveen; T P C Dorlo; S Nierkens; C A Lindemans; M A de Witte; A van Rhenen; R Raijmakers; M Bierings; J Kuball; A D R Huitema; J J Boelens Journal: Blood Adv Date: 2019-07-23
Authors: Jeannine S McCune; Donald E Mager; Meagan J Bemer; Brenda M Sandmaier; Barry E Storer; Shelly Heimfeld Journal: Cancer Chemother Pharmacol Date: 2015-05-17 Impact factor: 3.333
Authors: E Mohanan; J C Panetta; K M Lakshmi; E S Edison; A Korula; N A Fouzia; A Abraham; A Viswabandya; V Mathews; B George; A Srivastava; P Balasubramanian Journal: Bone Marrow Transplant Date: 2017-05-08 Impact factor: 5.483
Authors: Jurgen B Langenhorst; Thomas P C Dorlo; Erik M van Maarseveen; Stefan Nierkens; Jürgen Kuball; Jaap Jan Boelens; Charlotte van Kesteren; Alwin D R Huitema Journal: Clin Pharmacokinet Date: 2019-05 Impact factor: 6.447